![Thomas Mehrling](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Mehrling
Amministratore Delegato presso
HELIX BIOPHARMA CORP.
Patrimonio netto: 50 290 $ in data 31/07/2026
Profilo
Thomas J.
Mehrling is the founder of Laevoroc Oncology AG, founded in 2019, where Dr. Mehrling holds the title of Chief Executive Officer.
Dr. Mehrling was the founder of Mundipharma EDO GmbH, founded in 2013, where Dr. Mehrling held the title of Chief Executive Officer.
Dr. Mehrling is also the founder of Laevoroc Immunology AG..
Dr. Mehrling is Chief Executive Officer at Release Therapeutics SA since 2024.
Dr. Mehrling is Chief Executive Officer at Helix BioPharma Corp.
starting in 2025.
Dr. Mehrling is Chairman & Chief Executive Officer at Laevoroc Chemotherapy AG.
Dr. Mehrling was Managing Director-European Oncology at Mundipharma International Ltd. from 2003 to 2013.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 21/05/2026 | 47.000 ( 0,06% ) | 50 290 $ | 31/07/2026 |
Posizioni attive di Thomas Mehrling
| Società | Posizione | Inizio |
|---|---|---|
| HELIX BIOPHARMA CORP. | Amministratore Delegato | 10/04/2025 |
Laevoroc Oncology AG
 Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Amministratore Delegato | 01/02/2019 |
Release Therapeutics SA
 Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Amministratore Delegato | 27/06/2024 |
Precedenti posizioni note di Thomas Mehrling
| Società | Posizione | Fine |
|---|---|---|
Mundipharma EDO GmbH
 Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Amministratore Delegato | 01/07/2019 |
Mundipharma International Ltd.
 Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Corporate Officer/Principal | 01/01/2013 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
23
Relazioni di 1° grado
5
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Helix BioPharma Corp.
 Helix BioPharma Corp. Pharmaceuticals: MajorHealth Technology Develops drugs for the prevention and treatment of cancer | Health Technology |
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Develops and produces pharmaceutical products | Health Technology |
Release Therapeutics SA
Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Health Technology |
Mundipharma EDO GmbH
Mundipharma EDO GmbH Miscellaneous Commercial ServicesCommercial Services Engages in research and development of therapies for cancer | Commercial Services |
Laevoroc Oncology AG
Laevoroc Oncology AG BiotechnologyHealth Technology Develops and manufactures cancer immunotherapies | Health Technology |
